Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats.
Extracellular signal-regulated kinase (ERK) 1/2 is activated during acute phase of stroke and contributes to stroke pathology. We have found that acute treatment with MEK1/2 inhibitors decrease infarct size and neurological deficits two days after experimental stroke. However it is not known whether benefits of this inhibition persist long-term. Therefore, the aim of this study was to assess neuro
